TCG CROSSOVER
TCG X is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCG X invests in both private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCG X has investment teams in Palo Alto and New York City
TCG CROSSOVER
Industry:
Financial Services Health Care Venture Capital
Status:
Active
Contact:
650-798-5495
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Ulu Ventures
Ulu Ventures provides early-stage investments to enterprise cloud and smart data companies.
Zeev Ventures
Zeev Ventures is an early-stage venture fund that invests in technology, financial, e-commerce, and consumer service sectors.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-09-02 | Abivax | TCG Crossover investment in Post-IPO Equity - Abivax | 49.2 M EUR |
| 2022-08-25 | Aktis Oncology | TCG Crossover investment in Series A - Aktis Oncology | 84 M USD |
| 2022-06-02 | Upstream Bio | TCG Crossover investment in Series A - Upstream Bio | 200 M USD |
| 2022-02-23 | Plexium | TCG Crossover investment in Series B - Plexium | 102 M USD |
| 2021-11-09 | Arbor Biotechnologies | TCG Crossover investment in Series B - Arbor Biotechnologies | 215 M USD |
| 2021-10-20 | ShouTi | TCG Crossover investment in Series B - ShouTi | 100 M USD |
| 2021-09-15 | Alpine Immune Sciences | TCG Crossover investment in Post-IPO Equity - Alpine Immune Sciences | 91 M USD |
| 2021-07-27 | Artios Pharma | TCG Crossover investment in Series C - Artios Pharma | 110 M GBP |
| 2021-06-15 | RayzeBio | TCG Crossover investment in Series C - RayzeBio | 108 M USD |
| 2021-06-10 | Synthekine | TCG Crossover investment in Series B - Synthekine | 107.5 M USD |